reduction in risk of death or permanent ventilation (HR=0.53; P=0.005)1
*Event-free survival defined as time to death or permanent assisted ventilation (tracheostomy or ≥16 hours of ventilatory support per day for >21 continuous days in the absence of an acute reversible event).1
Patients treated with SPINRAZA had a 63% reduction in risk of death alone compared with untreated patients (84% SPINRAZA vs 61% untreated; HR=0.37; P=0.004).1
Review the warnings and precautions including thrombocytopenia, coagulation abnormalities, and renal toxicity
Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.